ClinVar Miner

Submissions for variant NM_001035.3(RYR2):c.10488T>G (p.Phe3496Leu)

gnomAD frequency: 0.00001  dbSNP: rs794728768
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000182784 SCV000235170 uncertain significance not provided 2013-06-04 criteria provided, single submitter clinical testing p.Phe3496Leu (TTT>TTG): c.10488 T>G in exon 72 of the RYR2 gene (NM_001035.2). The Phe3496Leu variant in the RYR2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Phe3496Leu results in a conservative amino acid substitution of one non-polar amino acid with another at a position that is conserved across species. The Phe3496Leu variant was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Nevertheless, no mutations in nearby residues have been reported in association with CPVT, indicating this region of the protein may be tolerant of change. Also, in silico analysis predicts Phe3496Leu is benign to the protein structure/function. We cannot definitively determine if Phe3496Leu is disease-causing mutations or a rare benign variants. The variant is found in CPVT panel(s).
Ambry Genetics RCV002399663 SCV002705746 uncertain significance Cardiovascular phenotype 2017-09-20 criteria provided, single submitter clinical testing The p.F3496L variant (also known as c.10488T>G), located in coding exon 72 of the RYR2 gene, results from a T to G substitution at nucleotide position 10488. The phenylalanine at codon 3496 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and leucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.